A new predictive model developed by Ochsner Health helps clinicians make real-time decisions for patients who had a stroke ...

Introduction ST-elevation myocardial infarction (STEMI) is one of the most prevalent presentations in young patients. It is ...

Exonerating a Delhi-based pulmonologist and hospital from charges of medical negligence while treating a patient diagnosed ...

Introduction: Hypoxic liver injury (HLI) and Killip classification are poor prognostic factors in patients with ST-segment elevation myocardial infarction (STEMI). This study investigates the ...

Unlike cerebral infarction, there is limited evidence to support the use of thrombolysis in SCI. This case report presents an 86‐year‐old male with multiple comorbidities who presented with ...

Platelet Membrane-Functionalized Hollow Mesoporous Prussian Blue Nanomedicine for Comprehensive Thrombolytic Management by Targeted Enhanced Fibrinolysis ... Nanomedicines Alleviate Oxidative Stress ...

Patients meeting any of the following criteria were excluded from the study: (1) no reperfusion or final Thrombolysis in Myocardial Infarction grade of 0 or 1, (2) emergent or urgent coronary artery ...

Acute myocardial infarction (AMI) remains a leading cause of mortality and morbidity worldwide, accounting for approximately 40%–50% of sudden cardiac deaths (Rallidis et al., 2022). Although prompt ...

In the ABYSS (Assessment of Beta-Blocker Interruption 1 Year After an Uncomplicated Myocardial Infarction on Safety and Symptomatic Cardiac Events Requiring Hospitalization) trial, interruption of ...

Options for intravenous thrombolytic agents other than alteplase and tenecteplase were further expanded in 2024. The RAISE trial compared reteplase with alteplase for acute ischaemic stroke treatment ...